Form D · Biotechnology

CRISPRQC INC.

San Diego, CA · CIK 0001916528

Offering snapshot reported Apr 2, 2025 · SEC filing

Reported sold: $3.89M
Investors reported: 14
Minimum accepted: $5K
First sale: Jan 2, 2024

Fundraising history

Reported sold

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

Reported sold$944,999 → $3,890,632
Reported investors2 → 14
Minimum accepted$25,000 → $5,000

Filing history

Scroll to see all columns →

Filed	Filing type	Reported sold	Change vs linked filing	Investors	Source
Apr 2, 2025	Amendment	$3,890,632	$2,945,633vs Feb 29, 2024	14	SEC filing
Feb 29, 2024	Amendment	$944,999	$44,999vs Feb 27, 2024	2	SEC filing
Feb 27, 2024	Initial	$900,000	No comparison	1	SEC filing
Mar 22, 2022	Initial	$885,000	No comparison	7	SEC filing

Offering details

Securities: Equity
Exemptions: 06b
Duration over one year: Yes
Business combination: No

Sales commissions: $0
Finders' fees: $0
Form D file number: 021-506176

Source: Form D, filed Apr 2, 2025. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
Name	Reported role
Kiana Aran	Director
George Bonaros	Director
Ross Bundy	Director, Executive
Paul Grint	Director
Ross Helgren Bundy	Executive
Michael Heltzen	Director
Toby Richardson	Director
Chris Yoo	Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:

8949 Kenamar Dr Ste 101
San Diego, CA, 92121